Evgen Pharma (LON:EVG) issued its quarterly earnings results on Tuesday. The company reported GBX (1.43) (($0.02)) EPS for the quarter, Digital Look Earnings reports.
Shares of EVG stock traded down GBX 0.10 ($0.00) on Thursday, hitting GBX 7.20 ($0.09). 68,181 shares of the company’s stock traded hands, compared to its average volume of 207,445. The stock has a market capitalization of $9.29 million and a price-to-earnings ratio of -2.67. The company’s fifty day simple moving average is GBX 9.90 and its 200 day simple moving average is GBX 15.22. Evgen Pharma has a one year low of GBX 5.50 ($0.07) and a one year high of GBX 33 ($0.43).
Separately, FinnCap restated a “corporate” rating on shares of Evgen Pharma in a report on Tuesday.
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Recommended Story: What is the float in trading stocks?
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.